Pluri Inc
Company Profile
Business description
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Contact
MATAM Advanced Technology Park
Building No. 5
Haifa3508409
ISRT: +972 747108600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
142
Stocks News & Analysis
stocks
Are declining Chinese births a red flag for A2 Milk?
stocks
Is this ASX share a value trap or bargain?
stocks
Goldman Sachs Earnings: Valuations remain stretched
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.60 | 16.20 | 0.18% |
| CAC 40 | 8,079.17 | 16.59 | 0.21% |
| DAX 40 | 24,559.86 | 143.26 | -0.58% |
| Dow JONES (US) | 48,747.01 | 258.42 | 0.53% |
| FTSE 100 | 10,151.04 | 24.26 | 0.24% |
| HKSE | 26,585.06 | 97.55 | 0.37% |
| NASDAQ | 23,090.65 | 136.33 | 0.59% |
| Nikkei 225 | 52,774.64 | 216.46 | -0.41% |
| NZX 50 Index | 13,417.17 | 156.76 | -1.15% |
| S&P 500 | 6,840.56 | 43.70 | 0.64% |
| S&P/ASX 200 | 8,782.90 | 14.00 | 0.16% |
| SSE Composite Index | 4,116.94 | 3.29 | 0.08% |